Cipla warns of headwinds in the second half after a shortfall in the second quarter

Business



[ad_1]

Cipla's second quarter net sales fell 1% to 3,948 crores. "Title =" Cipla's second quarter net sales fell 1% to 3,948 crores. "Clbad =" img-responsive "/> <p> Cipla's second quarter net sales dropped 1 Cipla Ltd, the second largest Indian pharmaceutical group by market capitalization, warned Monday against" multiple hurdles "in the second fiscal year after its quarterly profit was lower than badysts' estimates, the company recorded a drop of nearly 7.7%, recording its largest intraday decline since November 2017. Among the challenges ahead , include balancing the capacity of certain categories of factories and penalties, said Cipla in a post-profit presentation without giving further details. </p> <p> Increased Crude and Commodities </p> <p> Indian pharmaceutical companies have been penalized by weak sales in the United States, resulting in regulatory bans and warnings. s production plants have weighed on their profitability. Although price pressure remains in the United States, Cipla's North American operations increased by 23% in September. </p> <p> The company's profit for the second quarter fell nearly 11% from the previous year, to stand at Rs 377 billion, while sales slowed down in recent years. like India. </p> <p> Analysts expected an average profit of 456 million rupees for the quarter ended September 30, according to Refinitiv data. </p> <p> Sales in India were stable, while sales in South Africa fell by about 3%. , Said Cipla. Total net sales decreased 1% to 3,948 crores. </p> <div clbad= First published: Mon, November 5, 2018. 01:00 IST
[ad_2]
Source link

Tags

Powered by https://naaju.com/india | Designed by Naaju
© Copyright 2024, All Rights Reserved